<DOC>
	<DOCNO>NCT01385137</DOCNO>
	<brief_summary>RATIONALE : An omega-3 fatty acid-enriched nutritional supplement may help improve muscle bone pain stiffness cause hormone therapy patient breast cancer . PURPOSE : This randomized phase III trial study omega-3 fatty acid supplement treat muscle bone pain stiffness patient stage I , stage II , stage III breast cancer receive hormone therapy .</brief_summary>
	<brief_title>S0927 : Omega3-Fatty Acid Supp Treating Muscle &amp; Bone Pain &amp; Stiffness Pts W/Stg I , II , III Brst Canc Rec ' v Hormone Thpy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess whether omega-3-fatty acid compare placebo cause reduction bad joint pain and/or stiffness 12 week , measure modified Brief Pain Inventory ( BPI ) , woman early-stage breast cancer aromatase inhibitor ( AI ) -associated arthralgia . Secondary - To assess proportion patient report improve versus deteriorate joint pain omega-3-fatty acid versus placebo . - To assess proportion patient report improve versus deteriorate joint stiffness omega-3-fatty acid versus placebo . - To assess whether patient receive omega-3-fatty acid compare placebo decrease analgesic use increase AI adherence . - To assess whether patient receive omega-3-fatty acid compare placebo improve functioning , pain , stiffness knees/hips ( measure Western Ontario McMaster Universities Osteoarthritis , WOMAC ) score . - To assess whether patient receive omega-3-fatty acid improve functioning , pain , stiffness hand ( measure Modified Score Assessment Quantification Chronic Rheumatoid Affections Hands , M-SACRAH ) . - To assess whether patient receive omega-3-fatty acid compare placebo improve functional quality life measure Functional Assessment Cancer Therapy-Endocrine Subscale ( FACT-ES ) Trial Outcome Index ( TOI ) . - To assess whether patient receive omega-3-fatty acid report change well versus bad compare placebo measure Global Rating Change Scale . - To identify minimally important change WOMAC , M-SACRAH , FACT-ES Trial Outcome Index ( TOI ) use `` little good '' `` little bad '' responses patient-reported global rating change joint pain joint stiffness . - To assess whether patient receive omega-3-fatty acid compare placebo improve lipid profile measure triglyceride , HDL , LDL . - To assess toxicity omega-3-fatty acid compare placebo set . - To assess whether difference serum-free total estradiol level treatment omega-3-fatty acid compare placebo . - To explore whether CYP19A1 genotype correlate severity joint symptom predict response omega-3-fatty acid . ( exploratory ) - To explore change hormonal inflammatory serum biomarkers , IL6 , TNF-α , CRP . - To assess whether relationship change serum docosahexaenoic acid ( DHA ) EPA resolution joint symptom . - To establish cohort patient ( placebo group ) good characterize natural history syndrome . OUTLINE : This multicenter study . Patients stratify accord prior osteoarthritis ( yes v ) prior taxane use ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral omega-3-fatty acid twice daily ( BID ) three time daily ( TID ) 24 week absence disease progression unacceptable toxicity . - Arm II : Patients receive oral placebo BID TID 24 week absence disease progression unacceptable toxicity . Patients undergo blood sample collection baseline 12 24 week biomarker DNA analysis . Patients complete Brief Pain Inventory Short Form ( BPI-SF ) , Western Ontario McMaster Universities Osteoarthritis ( WOMAC ) Index , Modified-Score Assessment Quantification Chronic Rheumatoid Affections Hands ( M-SACRAH ) , FACT-ES Trial Outcome Index , Omega-3-fatty acid Dietary Intake questionnaires baseline 6 , 12 , 24 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary invasive adenocarcinoma breast Stage I , II , IIIA disease No metastatic disease Must undergone modify radical mastectomy breastsparing surgery recover Estrogenreceptor positive ( ER+ ) and/or progesteronereceptor positive ( PR+ ) Currently take thirdgeneration aromatase inhibitor ( AI ) [ e.g. , anastrozole ( Arimidex® ) , letrozole ( Femara® ) , exemestane ( Aromasin® ) ] ≥ 90 day prior registration plan continue ≥ 180 day registration Must complete S092 Brief Pain Inventory ( BPI ) Short Form within past 14 day , must worst pain/stiffness ≥ 5 BPI ( item # 2 ) start increase AI therapy PATIENT CHARACTERISTICS : Postmenopausal Zubrod performance status 02 Willing submit blood serumfree estradiol , total estradiol , serum inflammatory marker ( IL6 , TNFα , CRP ) , DHA EPA , lipid profile ( LDL , HDL , triglyceride ) , DNA analysis ( CYP19A1 ) Able complete study questionnaire English At least 5 year since malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , ductal carcinoma situ breast adequately treat stage I II cancer patient currently complete remission Patients must know allergy soy , give placebo suspend soybean oil PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 month since prior omega3 fatty acid supplement must agree refrain omega3fatty acid supplement source outside study More 28 day since prior investigational agent No medical therapy , alternative therapy , physical therapy joint pain/stiffness within past 30 day Patients must anticoagulation medication ( i.e. , heparin/warfarin ) increase risk bleeding within 28 day prior registration Patients must history bone fracture surgery afflict knee and/or hand within 6 month prior registration Patients must narcotics within 14 day registration Patients may receive corticosteroid treatment ; however , follow criterion apply : Patients must receive oral intramuscular corticosteroid within 28 day prior registration Patients must receive intraarticular steroid study , , joint within 28 day prior registration Patients must receive topical analgesic ( e.g. , capsaicin preparation ) study joint analgesic ( e.g. , opiates , tramadol ; exception nonsteroidal antiinflammatory drug ( NSAIDs ) acetaminophen ) within 14 day prior registration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>pain</keyword>
	<keyword>arthralgia</keyword>
</DOC>